drugset / Trial / NCT00446849

Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)

NCT00446849

Phase 4 Completed 290 enrolled Shire
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the percentage of subjects with clinical recurrence of UC at 6 months using MMX mesalamine once daily.

Timeline

Start
2007-05-01
Primary completion
2009-08-17
Completion
2009-08-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Mesalamine Small molecule 2.4 g Oral
Subject Mesalamine Small molecule 4.8 g Oral

Indications